 |
|
|
|
Expert Perspectives on Clinical Practice
|
|
|
Daily Clinical Updates from the 2011 Annual Hematology Meeting
in San Diego
|
|
|
|
|
Expert Interviews |
 |
Downloadable Slides |
 |
|
 |
|
Release Date
December 16, 2011
|
Expiration Date
December 16, 2012 |
|
|
| Faculty |
James O. Armitage, MD
University of Nebraska
Omaha, Nebraska, United States
|
Andrzej Jakubowiak, MD, PhD
University of Chicago
Chicago, Illinois, United States
|
|
Robert Chen, MD
City of Hope
Duarte, California, United States
|
Sagar Lonial, MD
Emory University
Atlanta, Georgia, United States
|
|
Myron Czuczman, MD
Roswell Park Cancer Institute
Buffalo, New York, United States
|
Ruben Mesa, MD
Mayo Clinic
Scottsdale, Arizona, United States
|
|
Meletios A. Dimopoulos, MD
University of Athens
Athens, Greece
|
Susan O'Brien, MD
University of Texas, M. D. Anderson Cancer Center
Houston, Texas, United States
|
|
Irene Ghobrial, MD
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
Srdan Verstovsek, MD, PhD
University of Texas, M. D. Anderson Cancer Center
Houston, Texas, United States
|
|
John Gribben, MD
St. Bartholomew’s Hospital
London, United Kingdom
|
Julie Vose, MD
University of Nebraska
Omaha, Nebraska, United States
|
|
Target Audience
This educational activity is specifically designed for hematologists, oncologists, and other healthcare providers interested and/or involved in the treatment of patients with hematologic malignancies.
|
Overview
These interviews discuss recently released data from the 2011 Annual Hematology Meeting in San Diego, focusing on various aspects of the management of patients with hematologic malignancies. |
Educational Objectives
Upon completion of this educational activity, participants should be able to:
-
Discuss the most recent clinical trial data regarding treatment of patients with hematologic malignancies such as leukemia, lymphoma, multiple myeloma, and myeloproliferative neoplasms
-
Describe emerging therapies and novel treatment strategies for patients with hematologic malignancies, and evaluate the practical utility of novel agents based on data from recent clinical studies
-
Examine the use of molecular markers and patient characteristics to guide the therapeutic decision-making process in patients with hematologic malignancies
-
Evaluate difficult or unusual problems encountered by the practicing hematologist/oncologist, and identify appropriate management options based on emerging data
|
Sponsorship
This activity is sponsored by prIME Oncology. |
Continuing Medical Education
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
|
prIME Oncology designates this enduring activity for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Each interview may provide the following credits:
2011593-1 MM FL (Jakubowiak/Ghobrial) – 0.5 credits
2011593-2 MM RR (Lonial/Dimopoulos) – 0.25 credits
2011593-3 HL (Armitage/Chen) – 0.25 credits
2011593-4 NHL (Vose/Czuzman) – 0.5 credits
2011593-5 CLL (O’Brien/Gribben) – 0.5 credits
2011593-6 MPN (Mesa/Verstovsek) – 0.25 credits
|
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this
CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you.
Links to the post tests are available on the video player pages.
|
Support Statement
This activity is supported by educational grants from Genentech; Merck & Co., Cephalon Oncology; Seattle Genetics, Inc.; Incyte; and Onyx Pharmaceuticals.
|
Disclosure of Conflicts of Interest
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Faculty Disclosures
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Dr Armitage has disclosed that he has received consulting fees from Seattle Genetics, GSK, Eisai, and Ziopharm. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Chen has disclosed that he has received fees as a consultant for Seattle Genetics. He has also performed contracted research for Seattle Genetics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Czuczman has disclosed that he has received consulting fees from Genentech, Celgene, Cephalon, and GlaxoSmithKline. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Dimopoulos has disclosed that he has received fees as a consultant for Onyx, Merck, and Celgene. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Ghobrial has disclosed that she has received consulting fees from Celgene, Millennium, Novartis, BMS, and Onyx. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Gribben has disclosed that he has received consulting fees from Roche, Celgene, MundiPharma, and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Jakubowiak has disclosed that he has received consulting fees from Millennium, Onyx, and Celgene. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Lonial has disclosed that he has received consulting fees from Millennium, Celgene, Novartis, Bristol-Myers Squibb, Onyx, and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Mesa has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr O’Brien has disclosed that she has received fees as a consultant for Bayer; Calistoga (Subsidiary of Gilead Sciences); Celgene Corporation; Cephalon; GlaxoSmithKline; MorphoSys; Pfizer; and Seattle Genetics, Inc. She has received fees as an Advisory Committee for AstraZeneca; CLL Global Research Foundation; and Pharmacyclics. She has also received fees as Research Support for Calistoga (Subsidiary of Gilead Sciences); Genentech BioOncology; Pharmacyclics; and Talon. She has also received fees as a speaker for The Medal Group. She has received fees for consulting for Genzyme. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Verstovsek has disclosed that he has performed contracted research for Incyte, Celgene, Roche, Geron, NS Pharma, Lilly Oncology, Bristol-Myers Squibb, YMBiosciences, Infinity Corporation, AstraZeneca, SBIO, and Gilead. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Vose has disclosed that she has performed contracted research for Allos Therapeutics; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Millennium; Onyx Pharmaceuticals; Pharmacyclics; S*Bio Pte, Ltd; Sanofi-Aventis US, Inc; and US Biotest, Inc. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
The employees of prIME Oncology have disclosed:
- Janelle Bowersox, RN (clinical) – no relevant financial relationships to disclose
- Chelsey Goins, PhD (clinical) – no relevant financial relationships to disclose
- Trudy Stoddert, ELS (editorial) – no relevant financial relationships to disclose
- Heather Tomlinson, MA (editorial) – no relevant financial relationships to disclose
- Susan H Yarbrough, CCMEP (compliance) – no relevant financial relationships to disclose
|
Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|
|
|
|
|
|
|
|
|
|
|
|
|
